Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination With Pembrolizumab or Chemotherapy in Patients With Lymphoma or Solid Tumor Malignancies

NCT03884556 is registered in ClinicalTrials.gov with Trishula Therapeutics, Inc. as lead sponsor.

NCT NCT03884556
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03884556 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination With Pembrolizumab or Chemotherapy in Patients With Lymphoma or Solid Tumor Malignancies
Lead sponsor
Trishula Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
April 10, 2019
Completion date
September 29, 2023
Enrollment
56 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, solid tumor